Levodopa ( DrugBank: Levodopa )

6 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	637
17	多系統萎縮症	2
90	網膜色素変性症	1
140	ドラベ症候群	1
164	眼皮膚白皮症	1
201	アンジェルマン症候群	3

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 10 of 637 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04147949 (ClinicalTrials.gov)	August 2022	27/10/2019	AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia	Randomized, Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Phase 2 Study to Test Effi ...	Parkinson Disease;Dyskinesia, Medication-Induced;L-Dopa Causing Adverse Effects in Therapeutic Use	Drug: AV-101;Drug: Placebo	VistaGen Therapeutics, Inc.	NULL	Not yet recruiting	30 Years	80 Years	All	20	Phase 2	NULL
2	NCT05312632 (ClinicalTrials.gov)	April 5, 2022	28/3/2022	A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopain P ...	A Multi-center, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Safinamide Mesilate a ...	Parkinson Disease	Drug: Safinamide Mesilate	Eisai Korea Inc.	NULL	Recruiting	19 Years	N/A	All	199	Phase 4	Korea, Republic of
3	EUCTR2020-002754-24-DE (EUCTR)	19/01/2022	14/06/2021	Clinical study in early PD patients to investigate the effect of Opicapone 50mg or Levodopa100 mg in ...	A randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study ...	Parkinson's Disease (PD) MedDRA version: 20.0;Level: HLT;Classification code 10034005;Term: Parkinso ...	Trade Name: Ongentys 50 mg hard capsules INN or Proposed INN: Ongentys 50 mg hard capsules Other descr ...	Bial - Portela & Ca, S.A.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 4	Portugal;Spain;Germany;United Kingdom;Italy
4	NCT05094050 (ClinicalTrials.gov)	January 18, 2022	20/10/2021	Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult ...	Parkinson's Disease: A Comparative Study of Levodopaand Carbidopa Bioavailability Following Foslevod ...	Parkinson's Disease	Drug: ABBV-951	AbbVie	NULL	Active, not recruiting	30 Years	N/A	All	16	Phase 1	United States
5	NCT05083260 (ClinicalTrials.gov)	January 4, 2022	23/9/2021	NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa	A Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study in Parkinson's ...	Parkinson Disease	Drug: NE3107;Drug: placebo	BioVie Inc.	NULL	Completed	30 Years	80 Years	All	46	Phase 1/Phase 2	United States
6	NCT05523791 (ClinicalTrials.gov)	January 1, 2022	17/8/2022	Whey Protein Supplementation in Patients With Parkinson's Disease	Can we Add Whey Protein Supplementation in Patients With Parkinson's Disease Without Interfering Wit ...	Parkinson Disease	Dietary Supplement: Fortiral;Dietary Supplement: Mg++	Ospedale Generale Di Zona Moriggia-Pelascini	NULL	Completed	60 Years	N/A	All	51	N/A	Italy
7	NCT04952194 (ClinicalTrials.gov)	January 1, 2022	3/6/2021	Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease	Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease	Parkinson Disease	Drug: Stalevo;Drug: Carbidopa and Levodopa Controlled Release Tablets	Second Affiliated Hospital, School of Medicine, Zhejiang University	NULL	Recruiting	30 Years	70 Years	All	180	Phase 4	China
8	NCT04990284 (ClinicalTrials.gov)	November 29, 2021	27/7/2021	eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.	A Randomized, Parallel Group, Multicentre, Multinational, Prospective, Open-label Exploratory Study ...	Parkinson Disease	Drug: Opicapone;Drug: L-DOPA/DDCI	Bial - Portela C S.A.	NULL	Recruiting	30 Years	N/A	All	100	Phase 4	Germany;Italy;Portugal;Spain;United Kingdom
9	EUCTR2019-004235-23-SE (EUCTR)	13/11/2021	24/08/2021	Parkinson's Disease: An extension of Study M15-741 evaluating the safety and tolerability of ABBV-95 ...	An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily ex ...	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ...	Product Name: Foscarbidopa and Foslevodopa Product Code: ABBV-951 INN or Proposed INN: Foslevodopa Othe ...	Abbvie Deutschland GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 3	United States;Canada;Denmark;Australia;Russian Federation;Germany;Netherlands;Italy;United Kingdom;J ...
10	NCT05297201 (ClinicalTrials.gov)	November 2, 2021	17/2/2022	Efficacy, Safety and Pharmacokinetic Study of CPL500036 in Patients With Levodopa Induced Dyskinesia	Phase II, Double Blind, Randomized, Placebo Controlled, Parallel Group, Trial to Explore the Potenti ...	Parkinson Disease;Dyskinesia, Medication-Induced	Drug: CPL500036 - low dose;Drug: CPL500036 - high dose;Drug: Placebo	Celon Pharma SA	National Center for Research and Development, Poland	Recruiting	50 Years	80 Years	All	108	Phase 2	Poland

First Previous1 2 3 4 5…64Next Last

先頭へ

17. 多系統萎縮症

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01577992 (ClinicalTrials.gov)	December 2011	7/11/2011	Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Mul ...	Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Mul ...	Pain Threshold;Multiple System Atrophy	Drug: Levodopa test;Procedure: determination of objective and subjective pain threshold	University Hospital, Toulouse	Fondation de France	Completed	50 Years	80 Years	Both	42	N/A	France
2	NCT01044992 (ClinicalTrials.gov)	May 2002	6/1/2010	Motor Activation in Multiple System Atrophy and Parkinson Disease: a Positron Emission Tomography (P ...	Motor Activation in Patients With Multi Systemic Atrophy and Comparison With Parkinson Disease and D ...	Multisystemic Atrophy	Radiation: H215O PET;Drug: Levodopa	University Hospital, Toulouse	NULL	Completed	40 Years	75 Years	Both	38	N/A	France

First Previous1Next Last

90. 網膜色素変性症

臨床試験数 : 147 / 薬物数 : 176 - (DrugBank : 43) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 110

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02837640 (ClinicalTrials.gov)	June 2016	22/6/2016	Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa	The Effect of L-Dopa on the Progression of Retinitis Pigmentosa	Retinitis Pigmentosa	Drug: levodopa-carbidopa	Beirut Eye Specialist Hospital	NULL	Recruiting	10 Years	65 Years	Both	50	Phase 2	Lebanon

First Previous1Next Last

140. ドラベ症候群

臨床試験数 : 116 / 薬物数 : 65 - (DrugBank : 17) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 64

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs041190116	17/02/2020	17/02/2020	3D gait analysis and L-DOPA in Dravet syndrome.	3D gait analysis and effectiveness of L-DOPA on pathological gait in Dravet syndrome.	Dravet syndrome(severe myoclonic epilepsy in infant) Dravet syndrome, severe myoclonic epilepsy in i ...	Arm A:0) 3D gait analysis and RS-fMRI before medication 1) levodopa/carbidopa(5mg/kg/day or 300mg/da ...	Natsume Jun	NULL	Recruiting	>= 6age old	Not applicable	Both	20	Phase 4	Japan

First Previous1Next Last

164. 眼皮膚白皮症

臨床試験数 : 15 / 薬物数 : 54 - (DrugBank : 34) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 141

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01663935 (ClinicalTrials.gov)	October 17, 2012	9/8/2012	Vision Response to Dopamine Replacement	Interventional Study of Levodopa Replacement on Retinal Function in Oculocutaneous Albinism	Albinism;Oculocutaneous Albinism	Drug: Levodopa/carbidopa	University of Wisconsin, Madison	NULL	Terminated	3 Years	N/A	All	20	Phase 2	United States

First Previous1Next Last

201. アンジェルマン症候群

臨床試験数 : 25 / 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 20

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03235037 (ClinicalTrials.gov)	November 26, 2013	28/7/2017	Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	Angelman Syndrome	Drug: Levodopa	Bennett Lavenstein	NULL	Completed	18 Months	16 Years	All	10	N/A	NULL
2	NCT01281475 (ClinicalTrials.gov)	January 2011	20/1/2011	A Trial of Levodopa in Angelman Syndrome	A Phase 2 Randomized Placebo-Controlled Trial of Levodopa in Angelman Syndrome	Angelman Syndrome	Drug: Levodopa;Drug: Placebo Oral Capsule	Wen-Hann Tan	Rady Children's Hospital, San Diego;University of California, San Francisco;Baylor College of Medici ...	Completed	4 Years	12 Years	All	67	Phase 2/Phase 3	United States
3	NCT00829439 (ClinicalTrials.gov)	January 2009	26/1/2009	Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome	A Dose-escalation Tolerability Study of Levodopa/Carbidopa in Angelman Syndrome	Angelman Syndrome	Drug: Levodopa/Carbidopa (4:1)	Boston Children’s Hospital	NULL	Completed	4 Years	12 Years	All	16	Phase 1	United States

First Previous1Next Last

先頭へ